Chen AP, O’Sullivan Coyne G, Wolters PL, Wolkenstein P. Clinical benefits of selumetinib in adults with neurofibromatosis type 1 – Authors’ reply. Lancet. 2025 Dec 13;406(10521):2754-2755. doi: 10.1016/S0140-6736(25)02248-2. PMID: 41390208.

Peyrottes A, Auclin E, Timsit MO, Branger N, Doumerc N, Waeckel T, Bigot P, Surlemont L, Knipper S, Pignot G, Bruyère F, Fontenil A, Parier B, Champy C, Rouprêt M, Patard JJ, Henon F, Fiard G, Guillotreau J, Beauval JB, Michel C, Bernardeau S, Taha F, Mallet R, Panthier F, Guy L, Vignot L, Khene ZE, Bernhard JC, Méjean A, Audenet F. Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide Cohort. Eur Urol Open Sci. 2025 Nov 13;82:185-191. doi: 10.1016/j.euros.2025.10.023. PMID: 41322956; PMCID: PMC12663658.

Deluegue L, Margue G, Cadart L, Bernhard JC, Bensalah K, Bigot P, Doumerc N, Bruyere F, Roupret M, Branger N, Surlemont L, Champy C, Parier B, Paparel P, Waeckel T, Lang H, Michel C, Fontenil A, Beauval JB, Patard JJ, Vallee M, Guillotreau J, Traxer O, Guy L, Audenet F, Rouget B, Olivier J, Fantoni JC. Local recurrence after R0 partial nephrectomy for RCC: insights from a large multicenter cohort (PREPARE study – UroCCR 140). World J Urol. 2025 Nov 26;44(1):3. doi: 10.1007/s00345-025-06093-3. PMID: 41296078.

Fertitta L, Sarin KY, Romo CG, Bergqvist C, Blakeley JO, Peiffer B, Tran VT, Armand ML, Moryousef S, Ferkal S, Le Corvoisier P, Ezzedine K, Wolkenstein P. Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: Development, validation and severity strata of the cNF-PUSH-D. Br J Dermatol. 2025 Nov 26:ljaf479. doi: 10.1093/bjd/ljaf479. Epub ahead of print. PMID: 41290043.

Hoisnard L, Sbidian E. Infectious risk with JAKi: What about atopic dermatitis? J Eur Acad Dermatol Venereol. 2025 Dec;39(12):2024-2025. doi: 10.1111/jdv.70116. PMID: 41287441.

Bettuzzi, Thomas et al. “Incidence, In-Hospital and Long-Term Mortality, and Sequelae of Epidermal Necrolysis in Adults.”
JAMA dermatology, e243575. 2 Oct. 2024, doi:10.1001/jamadermatol.2024.3575

Nicol, Edith et al. “Preformulation evaluation of selumetinib for topical application: skin distribution and photodegradation analysis using MALDI imaging and LC-MS/MS.”
Pharmaceutical development and technology vol. 29,8 (2024): 855-861. doi:10.1080/10837450.2024.2405829

Pacot, Laurence et al. “Prenatal diagnosis for neurofibromatosis type 1 and the pitfalls of germline mosaics.”
NPJ genomic medicine vol. 9,1 41. 8 Sep. 2024, doi:10.1038/s41525-024-00425-9

Leboyer, Marion et al. “Low-dose interleukin-2 in patients with bipolar depression: A phase 2 randomised double-blind placebo-controlled trial.”
Brain, behavior, and immunity, vol. 123 177-184. 4 Sep. 2024, doi:10.1016/j.bbi.2024.09.005

Fontana, Marianna et al. “Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.”
The New England journal of medicine, 10.1056/NEJMoa2409134. 30 Aug. 2024, doi:10.1056/NEJMoa2409134

Skorobogatov, Katrien et al. “Immune-based Machine learning Prediction of Diagnosis and Illness State in Schizophrenia and Bipolar Disorder.”
Brain, behavior, and immunity vol. 122 (2024): 422-432. doi:10.1016/j.bbi.2024.08.013

Pina Vegas, Laura et al. “Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS).”
RMD open vol. 10,3 e004631. 7 Aug. 2024, doi:10.1136/rmdopen-2024-004631

Boukouaci, Wahid et al. “B Cell-activating factor (BAFF): A promising trans-nosographic biomarker of inflammation and autoimmunity in bipolar disorder and schizophrenia.”
Brain, behavior, and immunity vol. 121 (2024): 178-188. doi:10.1016/j.bbi.2024.07.025